Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Should patients with relapsing multiple sclerosis be given a higher dose and frequency of interferon-β1a?

Nature Clinical Practice Neurology volume 1, pages 16–17 (2005)Cite this article

boxed-textSchwid SR et al. (2005) Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis. Arch Neurol 62: 785–792

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Panitch H et al. (2002) Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 59: 1496–1506

    Article  CAS  Google Scholar 

  2. Rask C et al. (online 7 March 2002) Comparative study of Rebif to Avonex and orphan exclusivity. [http://www.fda.gov/cder/biologics/review/ifnbser030702r1.pdf] (accessed 6 July 2005)

    Google Scholar 

  3. de la Fuente-Fernández R et al. (2001) Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 293: 1164–1166

    Article  Google Scholar 

  4. Wager TD et al. (2004) Placebo-induced changes in FMRI in the anticipation and experience of pain. Science 303: 1162–1167

    Article  CAS  Google Scholar 

  5. Francis GS et al. (2005) Interferon β-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 65: 48–55

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Emma Campbell, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Mellen Center for Multiple Sclerosis Treatment and Research,

    Robert J Fox & Richard A Rudick

  2. Director of the Mellen Center for Multiple Sclerosis Treatment and Research,

    Robert J Fox & Richard A Rudick

  3. Chairman of the Division of Clinical Research at the Cleveland Clinic Foundation, Cleveland, OH, USA

    Robert J Fox & Richard A Rudick

Authors
  1. Robert J Fox
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard A Rudick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert J Fox.

Ethics declarations

Competing interests

Drs Fox and Rudick have received grant support or honoraria for speaking and consulting services in the past 3 years from Accorda Therapeutics, Biogen Idec, Centocor, Merck, Millenium, National Institutes Of Health, National Multiple Sclerosis Society, Questcor, Serono, Teva Neuroscience and Vertex Pharmaceuticals.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fox, R., Rudick, R. Should patients with relapsing multiple sclerosis be given a higher dose and frequency of interferon-β1a?. Nat Rev Neurol 1, 16–17 (2005). https://doi.org/10.1038/ncpneuro0041

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneuro0041

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing